BioSpace News Archive

Minerva Surgical, Inc. (Minerva Surgical), a women’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today announced the closing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of $12.00 per share.

Valneva SE, a specialty vaccine company, announced the publication of an amendment filed with the French Financial Markets Authority on October 26, 2021 under the filing number D.21-0286-A01 to its 2020 Universal Registration Document, filed with the AMF on April 9, 2021 under the filing number D.21-0286.

Mitrix Bio announced a preview paper discussing recently discovered blood components called “Mitlets,” small vesicles containing mitochondria, ejected by platelets, which potentially could be transfused into patients to treat disease.

Medigen Vaccine Biologics Corp vaccine candidate, MVC-COV1901, has been recommended by an independent vaccine prioritisation advisory group to be included in the World Health Organisation Solidarity Trial Vaccines.

Moderna, Inc. (Nasdaq: MRNA), today announced the first participant has been dosed in the Phase 3 pivotal registration study of mRNA-1647, the Company’s cytomegalovirus (CMV) vaccine candidate.

Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2021 after market close on Monday, November 8th, 2021

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today it will release its third quarter financial results on Tuesday, November 9, 2021.

Xilio Therapeutics, Inc. (Xilio) a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today announced the closing of its previously announced initial public offering of 7,353,000 shares of its common stock at a price to the public of $16.00 per share.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report financial results for the three and nine months ended September 30, 2021 after the close of the U.S. financial markets on Tuesday, November 9, 2021 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

Cortexyme, Inc. (Nasdaq: CRTX) today reported top-line results from its Phase 2/3 GAIN Trial, a double-blind, placebo-controlled study evaluating the efficacy of atuzaginstat (COR388), an investigational orally administered small-molecule that targets gingipain proteases from the bacterium Porphyromonas gingivalis (P. gingivalis).